Skip to main content
Editorial06 October 2022
Editorial: Quality of care of glioma patients

Over many decades, extent of tumor resection and overall survival were almost the sole parameters by which treatment success and quality of care of glioma patients had been measured. With the advent of new systemic therapy approaches and new imaging technologies, with the increasing understanding of brain connectivity and of molecular mechanisms of glioma disease, an individualized patient-centered therapy for glioma has evolved. Thus, today, many patients, especially patients with IDH-mutated gliomas with a more favorable prognosis, see themselves confronted with a chronic disease rather than with an end-of-life perspective immediately after tumor diagnosis.

As a consequence, quality of care of glioma patients has been brought into the focus, mainly encompassing high-quality and shared decision making1 , excellent performance, outcome measures and treatment accessibility2. However, with regard to high-end techniques, complex quality and process management and the holistic approach towards patients considering their biopsychosocial situation, quality of care in this context still is defined to high-income countries. This applies even more for patients with brain tumors, for whom highest incidence rates have been found in countries with high sociodemographic index levels, reflecting the lack of accessibility of advanced and costly imaging technologies as well as advanced neurological and neurosurgical services in many areas of the world3, 4. Moreover, due to population growth, ageing as well as the environmental and socioeconomic situation of health care - including rising inflation and the shortage of qualified healthcare workers – the maintenance of quality of care of glioma patients will be challenging in the future.

Having all these healthcare system and healthcare service quality issues in mind, we aimed at gathering new insights into the current quality of care of glioma patients in this special Research Topic.

Neurocognition and Quality of life

A discussion on what quality of care means in lower-grade glioma patients has been provided by Taillandier et al., pointing out the importance of an “interactive patient-centered medicine”. In their opinion article they elaborate on the limitations of randomized-controlled trials in neuro-oncology and argue in favor of well conducted observational studies in order to understand the long-term evolution of glioma, with respect to neurocognitive and health-related quality of life (QoL) parameters instead of solely molecular markers.

Neurocognition and QoL is the topic of six publications in this article collection. Van Kessel et al. investigated whether glioma patients´ preoperative neurocognitive performance had an impact on survival. They found that memory function added prognostic value in high-grade glioma patients (additionally to established pre-selected predictors), but not in patients with low-grade glioma. Dufner et al. pointed out the importance of assessing patients´ psychosocial burden and mood disturbances during adjuvant tumor treatment, given the relation of depression and chemotherapy-induced nausea and vomiting. Two publications focused on the neurocognitive consequences of awake glioma surgery. Staub-Bartelt et al. found that planned awake surgery had no negative impact on the prevalence of distress, anxiety or depression in glioma patients. Reitz et al. observed not only a high number of patients experiencing anxiety and depression prior to awake surgery, but also clear improvements in this and all other neurocognitive domains at long-term postoperative follow-up. Moreover, all patients in their cohort were seizure-free after awake surgery, albeit under anti-convulsive medication in 81.5% of patients. Robe et al. equally addressed postoperative outcome concerning seizure-freedom in patients with low-grade glioma, and the benefits of early surgery in these patients. Thus, patients undergoing early surgery for low-grade glioma significantly later lost their ability to work after tumor diagnosis than patients who underwent tumor resection at least 6 months after diagnosis.

Neurological function and frailty assessments

However, patients´ pre- and postoperative neurological function, and thus, quality of life, clearly depends on glioma localization and invasion of eloquent regions. Thus, Coburger et al. reported on 83 patients with lower grade glioma (WHO grade II and III, according to the WHO 2016 classification) situated in regions involving motor and/or language function and observed permanent new postoperative deficits in 38.6% of their patients three months after surgery. They found that permanent new neurological deficits after surgery significantly correlated with preoperative neurological impairment and complete tumor resection.

While these authors did not address overall survival of their patients, another publication within this Research Topic, provided by Kasper et al., focusing on glioblastoma patients, found a clear association between patients´ neurological function after surgery and overall survival. Similarly, Krenzlin et al. reported on a significant correlation of patients´ frailty, assessed by The Geriatric 8 health status screening tool (G8) and Groningen Frailty Index (GFI), and overall survival.

However, although QoL has increasingly been put into the focus of clinical trials of glioma patients, clinical assessment practice of patient-reported outcomes (PROs) still remains very heterogenous, as shown by Weiss-Lucas et al. Investigating the use of PRO and neurocognition assessment practices throughout departments of surgical neuro-oncology in Germany, they observed that only a small majority of departments performed patient-centered screenings outside of clinical trials. As a consequence, the authors recommended a minimum number of PRO and neurocognitive assessments for routine clinical practice in their publication.

Quality indicators and adverse events

While quality of care ultimately aims at excellent patient outcomes, quality of care highly depends on process quality. Besides defining quality indicators for quality of care assessments5, detecting and reporting on adverse events and complications are therefore essential for continuously improving processes, and thus, improving the quality of care. Vecchio TG et al. addressed the issue of adverse events following surgery in lower-grade gliomas, using the Landriel–Ibanez classification (LIC) and the Therapy-Disability-Neurology (TDN) score, reporting on postoperative complications in 47.6% of their patients. Katzendobler et al. equally focused on severe adverse events; however, after stereotactic biopsies in 617 glioma patients, they only identified severe postoperative complications including complications requiring an intervention in 1.2% of cases. Moreover, they succeeded to establish an integrated diagnosis by stereotactic biopsy in 96.4% of their patients.

Novel prognostic biomarkers

Regarding diagnosis and the prognostic value of gene expression profiling, Liu et al. reported on Guanine nucleotide-binding protein subunit gamma 12 (GNG12) as a novel biomarker, with high levels of GNG 12 expression representing an independent risk factor for poor prognosis in patients with glioma, regardless of the presence of IDH mutations or 1p/19q co-deletions.

Uncommon co-morbidities and tumor presentations in adults with gliomas

The remaining two articles in this Research Topic focus on clinical themes with a relatively rare incidence in adults with glioma. El Rahal et al. retrospectively analyzed 1800 glioblastoma patients of whom 2.1% had been treated for hydrocephalus by ventricular shunting. They observed symptomatic improvement in 95% of patients after shunting and the necessity of shunt revisions in 26.% of patients, and concluded that hydrocephalus treatment in glioblastoma patients “might maintain patients’ eligibility for crucial oncological therapy as well as quality of life”.

Finally, Liu et al. provided an analysis of 1257 patients with optic pathway gliomas and revealed OS rates of 93% 10 years after tumor diagnosis with treatments including surgery, radiation and chemotherapy not resulting in better prognoses.

To summarize, this article collection includes remarkable publications on the quality of care of glioma patients and emphasizes again the multifaceted nature of the research topic. We thank all the authors, colleagues and the team of Frontiers who contributed to this work.

1,753 views

1 citations

ORIGINAL RESEARCH
19 July 2022
GNG12 as A Novel Molecular Marker for the Diagnosis and Treatment of Glioma
Runze Liu, 8 more and Yanzheng Gao

3,757 views

15 citations

ORIGINAL RESEARCH
3 March 2022
Eloquent Lower Grade Gliomas, a Highly Vulnerable Cohort: Assessment of Patients’ Functional Outcome After Surgery Based on the LoG-Glio Registry
Jan Coburger, 21 more and Andrej Pala

3,452 views

15 citations

ORIGINAL RESEARCH
9 March 2022
Early Surgery Prolongs Professional Activity in IDH Mutant Low-Grade Glioma Patients: A Policy Change Analysis
Pierre A. Robe, 7 more and Tom J. Snijders

3,300 views

14 citations

ORIGINAL RESEARCH
15 February 2022
The Emesis Trial: Depressive Glioma Patients Are More Affected by Chemotherapy-Induced Nausea and Vomiting
Vera Dufner, 9 more and Herwig Strik

4,496 views

8 citations

ORIGINAL RESEARCH
7 April 2022
Neurocognitive Outcome and Seizure Freedom After Awake Surgery of Gliomas
Sarah Christina Reitz, 8 more and Marie-Therese Forster

3,151 views

9 citations

Epidemiology and Survival of Patients With Optic Pathway Gliomas: A Population-Based Analysis
ORIGINAL RESEARCH
11 February 2022
Epidemiology and Survival of Patients With Optic Pathway Gliomas: A Population-Based Analysis
Huanbing Liu, 4 more and Yubo Wang

5,697 views

23 citations

6,626 views

16 citations

ORIGINAL RESEARCH
17 January 2022
Impact of Anticipated Awake Surgery on Psychooncological Distress in Brain Tumor Patients
Franziska Staub-Bartelt, 3 more and Marion Rapp

3,938 views

13 citations

ORIGINAL RESEARCH
2 December 2021
The Prognostic Value of NANO Scale Assessment in IDH-Wild-Type Glioblastoma Patients
Johannes Kasper, 7 more and Felix Arlt

3,150 views

7 citations

ORIGINAL RESEARCH
30 November 2021
Frailty in Glioblastoma Is Independent From Chronological Age
Harald Krenzlin, 5 more and Naureen Keric

3,311 views

27 citations

ORIGINAL RESEARCH
18 November 2021
Added Value of Cognition in the Prediction of Survival in Low and High Grade Glioma
Emma van Kessel, 8 more and Tom J. Snijders

3,449 views

10 citations